Wealthfront Advisers
AZN icon

Wealthfront Advisers’s AstraZeneca AZN Stock Holding History

Wealthfront Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
1,203
+32
+3% +$6.02K ﹤0.01% 1051
2026
Q1 		$231K Sell
1,171
-1,122
-49% -$216K ﹤0.01% 998
2025
Q4 		$422K Buy
+2,293
New +$402K ﹤0.01% 854

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wealthfront Advisers's AZN Position: Q2 2026 in Review

Wealthfront Advisers increased its AstraZeneca (AZN) stake by 2.7% in Q2 2026, buying an estimated $6.02K and bringing the position to 1,203 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Wealthfront Advisers first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $422K in Q4 2025. 1,149 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Wealthfront Advisers held 1,203 shares of AstraZeneca worth $228K as of Q2 2026.
  • Wealthfront Advisers bought 32 AstraZeneca shares in Q2 2026, an estimated $6.02K.
  • AstraZeneca made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1051 holding.
  • Wealthfront Advisers first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Wealthfront Advisers's AstraZeneca position peaked at $422K in Q4 2025.
  • 1,149 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.